Curbside Consultation in IBD: 49 Clinical Questions, Second Edition

David T Rubin, MD; Sonia Friedman, MD; Francis A Farraye, MD MSc

Question 7: How Should We Be Using C-Reactive Protein And Fecal Markers, Such As Lactoferrin Or Calprotectin, In Our Patients? (continued)

Severine Vermeire, MD, PhD; Marc Ferrante, MD, PhD; Paul Rutgeerts, MD, PhD

Biomarkers are commonly used in inflammatory bowel disease (IBD) patients in various clinical settings, including during work-up of a patient suspected of having IBD and in the differential diagnosis with other disorders causing chronic diarrhea, abdominal cramps, and blood or mucus discharge. Once the diagnosis of IBD has been established, biomarkers remain part of the followup to assess disease activity and monitor the effect of therapies. At present there is no single gold standard marker. Instead, various biomarkers are being used, of which C-reactive protein (CRP) and erythrocyte…